Over expression of PI3K-AkT reduces apoptosis and increases prostate size in benign prostatic hyperplasia

Area of Science:

• Urology
• Molecular Biology
• Oncology

Background:

• The phosphatidylinositol 3-kinase (PI3K)/AKT pathway and apoptosis are crucial in prostate cancer.
• Limited research exists on PI3K/AKT pathway gene expression and apoptotic protein levels in Benign Prostatic Hyperplasia (BPH) and their correlation with prostate size.

Purpose of the Study:

• To investigate the gene expression of PI3K/AKT pathway components.
• To analyze the protein expression of apoptotic factors.
• To determine the association between these molecular alterations and prostate size in BPH patients.

Main Methods:

• Gene expression of PI3K and AKT was quantified using quantitative PCR (q-PCR).
• Protein levels of apoptotic markers (BcL-2, caspase-3, caspase-9, BAD, p-BAD) were assessed via western blotting and immunohistochemistry.
• The study included 27 BPH patients aged 55-75 years.

Main Results:

• Significant upregulation of PI3K (p85-A), AKT1, and AKT2 gene expression was observed in BPH patients with larger prostates.
• Protein expression of BcL-2 and caspase-9 was also significantly elevated in larger prostates.
• These findings suggest a correlation between specific molecular pathways and prostate enlargement.

Conclusions:

• Overexpression of the PI3K/AKT pathway and BcL-2 is associated with reduced apoptosis.
• These molecular changes correlate with increased prostate size in Benign Prostatic Hyperplasia.
• The study highlights potential molecular targets for managing BPH progression.